Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia (Q37212915)

19 August 2017

1 reference

title

Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia (English)

1 reference

19 August 2017

0 references

0 references

1 reference

Mohamed A Kharfan-Dabaja

1

1 reference

19 August 2017

Julio C Chavez

2

1 reference

19 August 2017

Khadija A Khorfan

3

1 reference

19 August 2017

Javier Pinilla-Ibarz

4

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

113

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

897-906

1 reference

Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

National standardization of ZAP-70 determination by flow cytometry: The French experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

Unsolved issues in CLL biology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Clinical significance of CD38 expression in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

ZAP-70 levels do change in CLL but not very often

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Karyotypic evolution in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of UnmutatedVHGene in Patients With Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23671

7 January 2021

Identifiers

DOI

10.1002/CNCR.23671

1 reference

19 August 2017

1 reference